PDS Biotechnology Q1 net loss narrows

Overview

• U.S. immunotherapy developer's Q1 net loss narrows yr/yr, adjusted EPS loss improves

• Operating expenses fell, mainly due to lower clinical and manufacturing costs

Outlook

• Company did not provide specific financial or operational guidance for the current period in press release

Result Drivers

• LOWER CLINICAL COSTS - Co said decrease in research and development expenses was primarily due to lower clinical and manufacturing costs

• REDUCED ADMINISTRATIVE FEES - Co said general and administrative expenses fell mainly due to lower professional fees

Company press release: ID:nGNX55D1lV

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for PDS Biotechnology Corp is $4.50, about 309.1% above its May 12 closing price of $1.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.